OnKure Therapeutics (OKUR) Total Liabilities (2020 - 2026)
OnKure Therapeutics' (OKUR) quarterly Total Liabilities came in at $14.3 million in Q1 2026, up 55.31% YoY from $9.2 million in Q1 2025, and up 141.72% on a QoQ basis from $5.9 million in Q4 2025.
OnKure Therapeutics (OKUR) Total Liabilities (2020 - 2026) Analysis & Trends
OnKure Therapeutics (OKUR) has 7 years of Total Liabilities data on file, last reported at $14.3 million in Q1 2026.
- Quarterly Total Liabilities rose 55.31% year-over-year to $14.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.3 million (up 55.31% YoY) and the FY2025 annual result came in at $5.9 million, down 46.45% from the prior year.
- Total Liabilities advanced to $14.3 million in Q1 2026, from $5.9 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $15.5 million in Q2 2023 to a low of $1.8 million in Q2 2024.
- A 5-year average of $8.9 million and a median of $9.1 million in 2022 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2024 — Total Liabilities plunged 88.09% — and 2025, when it jumped 327.71%.
- Tracing OKUR's Total Liabilities over 5 years: stood at $8.2 million in 2022, then fell by 5.61% to $7.8 million in 2023, then soared by 42.94% to $11.1 million in 2024, then slumped by 46.45% to $5.9 million in 2025, then soared by 141.72% to $14.3 million in 2026.
- The last three Total Liabilities figures came in at $14.3 million (Q1 2026), $5.9 million (Q4 2025), and $6.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | OnKure Therapeutics | 196.98 Mn | 20.60 Mn | - | 7.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.25 Mn |
| Mar 31, 2026 | 14.34 Mn |
| Dec 31, 2025 | 5.93 Mn |
| Sep 30, 2025 | 6.41 Mn |
| Jun 30, 2025 | 7.90 Mn |
| Mar 31, 2025 | 9.23 Mn |
| Dec 31, 2024 | 11.08 Mn |
| Sep 30, 2024 | 3.63 Mn |
| Jun 30, 2024 | 1.85 Mn |
| Mar 31, 2024 | 3.40 Mn |
| Dec 31, 2023 | 7.75 Mn |
| Sep 30, 2023 | 15.44 Mn |
| Jun 30, 2023 | 15.51 Mn |
| Mar 31, 2023 | 11.78 Mn |
| Dec 31, 2022 | 8.21 Mn |
| Sep 30, 2022 | 10.46 Mn |
| Jun 30, 2022 | 9.45 Mn |
| Mar 31, 2022 | 9.09 Mn |
| Dec 31, 2021 | 6.81 Mn |
| Sep 30, 2021 | 6.74 Mn |